Repaglinide in the management of new-onset diabetes mellitus after renal transplantation

T. Türk, F. Pietruck, S. Dolff, A. Kribben, O. E. Janssen, K. Mann, T. Philipp, U. Heemann, O. Witzke

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

The purpose of this study was to investigate the use of the short-acting insulin secretion drug repaglinide in new-onset diabetes mellitus (NODM) after renal transplantation. Twenty-three Caucasian patients with NODM after renal transplantation were selected to receive repaglinide therapy and were followed for at least 6 months. A control group treated with rosiglitazone was chosen for comparison. Successful repaglinide treatment was defined as a significant improvement of blood glucose concentrations and HbA1c <7% in the absence of glucosuria and without the need for the addition of further anti-diabetic agents. After 6 months of treatment with repaglinide, 14 of the 23 patients were successfully treated. Mean HbA1c decreased from 7.6 ± 0.6% to 5.8 ± 0.6% in 14 patients treated successfully. In nine patients, hyperglycemia persisted, and they were switched to insulin treatment (HbA1c 8.5 ± 2.9% at the beginning to 7.4 ± 2.2%). Mean serum creatinine levels, cyclosporine A and tacrolimus blood levels did not change significantly following institution of repaglinide therapy. The rate of successful treatment and the degree of HbA1c decrease were similar compared to rosiglitazone-treated control patients. The data from our observational study indicate that repaglinide can be an effective treatment option in Caucasian patients with NODM after renal transplantation.

Original languageEnglish
Pages (from-to)842-846
Number of pages5
JournalAmerican Journal of Transplantation
Volume6
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Keywords

  • New-onset diabetes mellitus
  • Renal transplantation
  • Repaglinide

Fingerprint

Dive into the research topics of 'Repaglinide in the management of new-onset diabetes mellitus after renal transplantation'. Together they form a unique fingerprint.

Cite this